Reminder: Invitation to Roche ’s Pharma Day 2023
The Roche Investor Relations team would like to invite you to the Roche Pharma Day that will take place in London on Monday, 11 September 2023, starting at 10:00 BST and finishing at 14:30 BST with a reception.The Roche Pharma Day will address the following topics: Group / Pharma strategyCommercial growth driversPipeline updatesOncology, Hematology, Neuroscience, Ophthalmology, Immunology Presenters include:ThomasSchinecker, CEO Roche GroupTeresa Graham, CEO Roche PharmaceuticalsLevi Garraway, Chief Medical Officer and Head of Global Product DevelopmentCharlie Fuchs, Senior Vice President and Global Head of Oncology an...
Source: Roche Investor Update - August 31, 2023 Category: Pharmaceuticals Source Type: news
AstraZeneca jumps on IRA litigation bandwagon, raising concerns over'unintended consequences' in rare disease R & D
With one week to go until the Centers for Medicare and Medicaid Services (CMS) releases its list of ten drugs up for the first round of pricing negotiations, AstraZeneca is jumping into the legal b | The company cited concerns with the law's consequences for orphan drug development. AstraZeneca…#centersformedicare #medicaidservices #cms #astrazeneca #ira (Source: Reuters: Health)
Source: Reuters: Health - August 26, 2023 Category: Consumer Health News Source Type: news
New & #039;promising medicines & #039; fund may incentivise commercialisation of high price drugs with weak evidence on clinical benefits
A new fund to fast-track patient access to potentially valuable new medicines may incentivise the pharmaceutical industry to develop high priced drugs for rare diseases with weak evidence on clinical benefits.
Health economics and policy academics from the London School of Hygiene & Tropical Medicine (LSHTM), writing in the Journal of the Royal Society of Medicine, warn that if the NHS England Innovative Medicines Fund (IMF) is not implemented appropriately, it risks disincentivising the generation of essential evidence and could shift the financial burden from the pharmaceutical industry to the public finances. (Source: World Pharma News)
Source: World Pharma News - August 25, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Reminder: Invitation to Roche ’s Pharma Day 2023
The Roche Investor Relations team would like to invite you to the Roche Pharma Day that will take place in London on Monday, 11 September 2023, starting at 10:00 BST and finishing at 14:30 BST with a reception.The Roche Pharma Day will address the following topics: Group / Pharma strategyCommercial growth driversPipeline updatesOncology, Hematology, Neuroscience, Ophthalmology, Immunology Presenters include:Thomas Schinecker, CEO Roche GroupTeresa Graham, CEO Roche PharmaceuticalsLevi Garraway, Chief Medical Officer and Head of Global Product DevelopmentCharlie Fuchs, Senior Vice President and Global Head of Oncology...
Source: Roche Investor Update - August 23, 2023 Category: Pharmaceuticals Source Type: news
Optimizing Rare Disease Clinical Trials Through Patient Experience, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain invaluable insights into the challenges faced by rare disease clinical trials and how patient experience can be optimized to improve trial outcomes. Attendees will learn more about making a significant impact on rare disease research and improving the lives of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 21, 2023 Category: Pharmaceuticals Source Type: news
Government in talks with companies over pricing of rare diseases drugs
The court had in May set up a five-member National Rare Diseases' Committee (NRDC) to implement the Centre's rare diseases policy to ensure that its benefits reach patients. The panel held discussions with companies involved in research, manufacture and sale of therapies of rare diseases, including Sanofi, Sarepta and Roche, on July 17, the government informed the court earlier this month. (Source: The Economic Times)
Source: The Economic Times - August 17, 2023 Category: Consumer Health News Source Type: news
Rare Disease Market Access Consulting Firm Alkemi Ranks No. 395 on the 2023 Inc. 5000
With Three-Year Revenue Growth of 1,467 Percent, Vermont based Alkemi Ranks No. 395 Among America's Fastest-Growing Private Companies. The rapidly growing rare disease market, coupled with the extraordinary need for deep expertise, propels Alkemi's remarkable growth! MANCHESTER CENTER, Vt.... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 17, 2023 Category: Pharmaceuticals Tags: AWD SVY Source Type: news
Pediatric Clinical Trials: Tackling Clinical and Therapeutic Development Challenges Head-On, Upcoming Webinar Hosted by Xtalks
In this free webinar, explore strategies to address the unique challenges of developing improved medicines for children with both rare and non-rare diseases. Attendees will learn about innovative clinical trial solutions, including modern statistical methodology approaches, modeling,... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 16, 2023 Category: Pharmaceuticals Tags: FVT TDS TRI Source Type: news
Estate of Henrietta Lacks, whose immortal cell line has fueled medical research, sues drug developer Ultragenyx
Immortal cells cultivated more than 70 years ago from tiny pieces of tissues taken without consent by Johns Hopkins University researchers from cancer patient Henrietta Lacks landed rare disease treatment developer Ultragenyx Pharmaceutical Inc. in U.S. District Court to face a lawsuit from Lacks' family.
The suit claims Ultragenyx has "made a fortune" by using Lacks' "stolen cells as a factory to make (the company's) 'proprietary' gene therapy products." Ron Lacks, the grandson of Henrietta and … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 15, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Soleo Health opens pharmacy, infusion center in Blue Ash to serve Tri-State patients
A national health care provider serving patients with rare and ultra-rare diseases, Alzheimer ’s and more has expanded its U.S. footprint with a new location in the Greater Cincinnati region. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 11, 2023 Category: Pharmaceuticals Authors: Liz Engel Source Type: news
Mesothelioma Immunotherapy Receives Orphan Drug Designation
A novel therapy for mesothelioma has been given orphan drug designation by the U.S. Food and Drug Administration.
Avenge Bio, a biotechnology company working on a new treatment platform for immunotherapy, announced it was granted the designation for its drug AVB-001 in June. It is currently enrolling patients in ongoing phase 1 and phase 2 clinical trials for the treatment of advanced ovarian cancer, primary peritoneal mesothelioma and fallopian tube cancer.
AVB-001 is a new treatment being developed by Avenge Bio using its LOCOcyte immunotherapy platform to treat solid tumors. It’s a first-in-human, si...
Source: Asbestos and Mesothelioma News - August 9, 2023 Category: Environmental Health Authors: Lynette Zilio Tags: Clinical Trials/Research/Emerging Treatments Source Type: news
New AskBio CEO charts growth strategy
With the backing of parent company Bayer, AskBio is staying focused on finding cures for rare diseases as former CEO and co-founder Sheila Mikhail moves into an advisory role and a new leader takes the helm. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 8, 2023 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news
VANFLYTA (quizartinib), FDA Approved in the U.S. for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Aug. 4, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Daiichi Sankyo, Inc., as a specialty pharmacy provider for VANFLYTA® (quizartinib). VANFLYTA is indicated for use in combination with standard cytarabine an... (Source: McKesson News)
Source: McKesson News - August 4, 2023 Category: Information Technology Source Type: news
FibroGen limits rare-disease drug's access after clinical trial failure. Some parents say it was saving their kids' lives
'How long before my heart fails?' Tanner Edwards asked his mom after losing access to a FibroGen drug he's taken for six years for Duchenne muscular dystrophy. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 31, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
Alexion, AstraZeneca Rare Disease, announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). The agreement furthers Alexion and AstraZeneca's commitment to advancing next-generation genomic medicines with the addition of complementary pipeline assets and innovative technologies. (Source: World Pharma News)
Source: World Pharma News - July 31, 2023 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
